TABLE 4.
Variable and timeline | Placebo (n = 12) | Soy isoflavone treatment (n = 12) | P2 | P3 |
Arterial compliance | ||||
SBP (mm Hg) | ||||
Baseline | 140.7 ± 7.44 | 140.1 ± 8.3 | 0.86 | |
6 wk | 135.9 ± 9.8 | 137.3 ± 9.7 | 0.15 | |
DBP (mm Hg) | ||||
Baseline | 82.2 ± 8.7 | 82.8 ± 6.2 | 0.85 | |
6 wk | 79.5 ± 7.1 | 79.9 ± 6.0 | 0.57 | |
Large-artery elasticity index (mL/mm Hg · 100) | ||||
Baseline | 15.2 ± 8.3 | 12.3 ± 4.2 | 0.28 | |
6 wk | 13.8 ± 3.7 | 13.8 ± 3.8 | 0.34 | |
Small-artery elasticity index (mL/mm Hg · 100) | ||||
Baseline | 3.1 ± 1.6 | 3.0 ± 1.5 | 0.90 | |
6 wk | 3.5 ± 2.2 | 4.0 ± 2.5 | 0.61 | |
FBF and vascular resistance | ||||
Baseline FBF (mL · min−1 · 100 g−1 tissue) | ||||
Baseline | 2.06 ± 0.62 | 1.78 ± 0.46 | 0.22 | |
6 wk | 1.92 ± 0.55 | 1.55 ± 0.70 | 0.35 | |
PRH (mL · min−1 · 100 g−1 tissue)5 | ||||
Baseline | 23.1 ± 7.4 | 17.7 ± 3.8 | 0.03 | |
6 wk | 22.3 ± 8.0 | 17.0 ± 8.1 | 0.08 | |
Vascular resistance (pressure/flow)6 | ||||
Baseline | 71.1 ± 36.3 | 77.7 ± 26.8 | 0.62 | |
6 wk | 74.7 ± 37.5 | 86.3 ± 30.2 | 0.52 | |
24-h Ambulatory blood pressure monitoring | ||||
24-h Mean SBP (mm Hg) | ||||
Baseline | 132.0 ± 7.0 | 132.0 ± 6.5 | 0.99 | |
6 wk | 130.9 ± 8.2 | 129.7 ± 8.4 | 0.61 | |
24-h Mean DBP (mm Hg) | ||||
Baseline | 78.5 ± 7.9 | 78.7 ± 7.6 | 0.96 | |
6 wk | 77.8 ± 6.3 | 77.4 ± 6.3 | 0.62 | |
24-h Mean HR (beats/min) | ||||
Baseline | 78.2 ± 5.3 | 75.3 ± 5.1 | 0.19 | |
6 wk | 81.1 ± 9.8 | 76.2 ± 5.5 | 0.43 | |
Daytime mean SBP (mm Hg) | ||||
Baseline | 135.6 ± 5.7 | 137.5 ± 7.9 | 0.52 | |
6 wk | 134.6 ± 9.9 | 134.2 ± 6.8 | 0.59 | |
Daytime mean DBP (mm Hg) | ||||
Baseline | 81.0 ± 8.2 | 82.6 ± 8.2 | 0.62 | |
6 wk | 80.2 ± 7.0 | 81.1 ± 6.7 | 0.84 | |
Daytime mean HR (beats/min) | ||||
Baseline | 81.6 ± 6.6 | 77.9 ± 5.9 | 0.16 | |
6 wk | 84.7 ± 9.2 | 77.7 ± 5.8 | 0.12 | |
Nighttime mean SBP (mm Hg) | ||||
Baseline | 124.4 ± 10.4 | 121.0 ± 11.0 | 0.45 | |
6 wk | 121.8 ± 7.6 | 118.9 ± 11.2 | 0.74 | |
Nighttime mean DBP (mm Hg) | ||||
Baseline | 72.9 ± 7.9 | 70.0 ± 9.14 | 0.41 | |
6 wk | 70.6 ± 5.4 | 68.4 ± 7.0 | 0.68 | |
Nighttime mean HR (beats/min) | ||||
Baseline | 70.5 ± 8.1 | 69.9 ± 6.1 | 0.83 | |
6 wk | 71.7 ± 10.6 | 71.5 ± 7.4 | 0.94 | |
Dipper SBP (fraction)7 | ||||
Baseline | 0.25 ± 0.45 | 0.58 ± 0.52 | 0.11 | |
6 wk | 0.36 ± 0.51 | 0.67 ± 0.49 | 0.21 |
DBP, diastolic blood pressure; FBF, forearm blood flow; HR, heart rate; PRH, peak reactive hyperemia; SBP, systolic blood pressure.
Derived by using an independent-samples t test for the comparison between the placebo and treatment groups.
Derived by using a generalized linear model for the comparison between the placebo and treatment groups with adjustment for baseline measures.
Mean ± SD (all such values).
Represents the highest FBF after release of the brachial artery occlusion.
Change in forearm vascular resistance before ischemia to the maximum reduction in forearm vascular resistance during PRH (flow-mediated vasodilation).
Proportion of subjects whose average nighttime SBP dropped >10% compared with their average daytime SBP.